Exogenous melatonin as a treatment for secondary sleep disorders: A systematic review and meta-analysis.

Central Nervous System Depressants / pharmacology Humans Melatonin / pharmacology Sleep Stages / drug effects Sleep Wake Disorders / drug therapy
Melatonin Meta-analysis Secondary sleep disorders Sleep efficiency Sleep onset latency Total sleep time

Journal

Frontiers in neuroendocrinology
ISSN: 1095-6808
Titre abrégé: Front Neuroendocrinol
Pays: United States
ID NLM: 7513292

Informations de publication

Date de publication:
01 2019
Historique:
received: 17 02 2018
revised: 07 06 2018
accepted: 13 06 2018
pubmed: 18 6 2018
medline: 18 5 2019
entrez: 18 6 2018
Statut: ppublish

Résumé

Melatonin is a physiological indoleamine involved in circadian rhythm regulation and it is currently used for secondary sleep disorders supported by empirical evidence. A small amount of evidence and some controversial results have been obtained in some randomized controlled trials (RCT). The objective of this meta-analysis is to determine the efficacy of exogenous melatonin versus placebo in managing secondary sleep disorders. Literature retrieval of eligible RCT was performed in 5 databases (PubMed, Embase, Cochrane Library, ClinicalTrials.gov, and Web of Science). In total, 7 studies of 205 patients were included. Pooled data demonstrate that exogenous melatonin lowers sleep onset latency and increases total sleep time, whereas it has little if any effect on sleep efficiency. Although, the efficacy of melatonin still requires further confirmation, this meta-analysis clearly supports the use of melatonin as a management for patients with secondary sleep disorders.

Identifiants

DOI: 10.1016/j.yfrne.2018.06.004 PMID: 29908879
pubmed: 29908879
pii: S0091-3022(18)30014-1
doi: 10.1016/j.yfrne.2018.06.004
pii:
doi:

Substances chimiques

Central Nervous System Depressants 0
Melatonin JL5DK93RCL

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

22-28

Informations de copyright

Copyright © 2018 Elsevier Inc. All rights reserved.

Auteurs

Tian Li (T)

Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, Faculty of Life Sciences, Northwest University, 229 Taibai North Road, Xi'an 710069, China; Department of Biomedical Engineering, The Fourth Military Medical University, 169 Changle West Road, Xi'an 710032, China.

Shuai Jiang (S)

Department of Aerospace Medicine, The Fourth Military Medical University, 169 Changle West Road, Xi'an 710032, China.

Mengzhen Han (M)

Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, Faculty of Life Sciences, Northwest University, 229 Taibai North Road, Xi'an 710069, China.

Zhi Yang (Z)

Department of Biomedical Engineering, The Fourth Military Medical University, 169 Changle West Road, Xi'an 710032, China.

Jianjun Lv (J)

Department of Biomedical Engineering, The Fourth Military Medical University, 169 Changle West Road, Xi'an 710032, China.

Chao Deng (C)

Department of Cardiovascular Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, 277 Yanta West Road, Xi'an 710061, Shaanxi, China.

Russel J Reiter (RJ)

Department of Cellular and Structural Biology, UT Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA. Electronic address: reiter@uthscsa.edu.

Yang Yang (Y)

Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, Faculty of Life Sciences, Northwest University, 229 Taibai North Road, Xi'an 710069, China; Department of Biomedical Engineering, The Fourth Military Medical University, 169 Changle West Road, Xi'an 710032, China. Electronic address: yang200214yy@nwu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents du système nerveux central › Dépresseurs du système nerveux central › Exogenous melatonin as a treatment for...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Exogenous melatonin as a treatment for...
questionsmedicales.fr › Mélatonine › Exogenous melatonin as a treatment for...
questionsmedicales.fr › Phénomènes physiologiques de l'appareil locomoteur et du système nerveux › Phénomènes physiologiques du système nerveux › Sommeil › Phases du sommeil › Exogenous melatonin as a treatment for...
questionsmedicales.fr › Troubles mentaux › Troubles de la veille et du sommeil › Exogenous melatonin as a treatment for...